Table 2.
Medications present on admission along with route and dosing of azithromycin administration with median and maximum duration of the QTc, and length of hospital stay in patients with pre-existing QT prolongation admitted to a US tertiary-care hospital between November 2009 and June 2012
| Variable | Summary (N = 103) |
|---|---|
| Beta blocker at admission | 52 (50 %) |
| Type of beta blocker | |
| Metoprolol | 34 (33 %) |
| Carvedilol | 12 (12 %) |
| Atenolol | 4 (4 %) |
| Other | 2 (2 %) |
| Antidepressant at admission | 37 (36 %) |
| Type of antidepressant | |
| Sertraline | 16 (16 %) |
| Citalopram | 7 (7 %) |
| Paroxetine | 7 (7 %) |
| Other | 7 (7 %) |
| Antifungal at admission | 2 (2 %) |
| Type of antifungal | |
| Fluconazole | 2 (2 %) |
| Antipsychotic at admission | 6 (6 %) |
| Type of antipsychotic | |
| Quetiapine | 4 (4 %) |
| Other | 2 (2 %) |
| Initial azithromycin dose | |
| 250 mg | 9 (9 %) |
| 500 mg | 92 (89 %) |
| Other | 2 (2 %) |
| Route of azithromycin administration | |
| IV | 42 (41 %) |
| PO | 39 (38 %) |
| Both | 22 (22 %) |
| Days of azithromycin | 2 (1, 1, 4, 36) |
| Total dose of azithromycin (mg) | 1000 (250, 500, 2000, 9000) |
| QTc at admission (ms) | 474 (423, 460, 495, 583) |
| Longest QTc during admission (ms) | 485 (451, 464, 510, 583) |
| Length of stay (days) | 3.2 (0.5, 2.1, 7.0, 148) |
The sample median and descriptive statistics (minimum, 25th percentile, 75th percentile, maximum) are given for continuous variables